Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype
NCT ID: NCT02950441
Last Updated: 2017-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
12 participants
INTERVENTIONAL
2016-06-30
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measurement of NAD+ Synthesis in Human Skeletal Muscle
NCT04905446
NR Supplementation and Exercise
NCT04907110
Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
NCT06425042
NAD Supplementation Study
NCT03310034
Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults
NCT07284225
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The most efficient means to boost NAD+ in muscle appears to be oral delivery of NR, and participants will be supplemented with 1000mg NR (2x x250mg tablets twice daily) for 3 weeks.
* Hypothesis: elevating skeletal muscle NAD+ bioavailability using NR supplementation will increase markers of mitochondrial function and that will manifest as a more favourable metabolic profile.
* Study Setting: the study will be carried out at the NIHR/Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicotinamide Riboside
1000mg (2x250mg tablets twice daily)
Nicotinamide Riboside
Placebo
Two tablets twice daily
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotinamide Riboside
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 70-80 years
* BMI 20-30kg/m2
* Participants who are able to discontinue aspirin for 3 days prior to the muscle biopsy
* Participants who are able to discontinue statins and vitamin D supplements for a week before the second visit and for the duration of the study
Exclusion Criteria
* Significant past medical history including diabetes mellitus, ischaemic heart disease, cerebrovascular disease, significant respiratory disease requiring medication, epilepsy
* High blood pressure (BP\>160/100mmHg)
* Oral Anticoagulants (like Warfarin, Dabigatran, Rivaroxaban) or Clopidogrel therapy which will increase the risk of bruising following a muscle biopsy
70 Years
80 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gareth Lavery, PhD
Role: PRINCIPAL_INVESTIGATOR
Institute of Metabolism and Systems Research, University of Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, West Midlands, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG_15-152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.